Castle Biosciences für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2PNH3 / ISIN: US14843C1053

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Historisch			Analysen

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Nachrichten zu Castle Biosciences Inc Registered Shs

11:34		Are Biotech And Pharma Stocks Poised To Keep Climbing After Hitting 52-Week Highs? (RTTNews)
04.11.25		Castle Biosciences Stock Surges 19% After Q3 Results And Guidance Raise (RTTNews)
04.08.25		Castle Biosciences Inc. Reveals Decline In Q2 Bottom Line (RTTNews)
23.07.25		Castle Biosciences Gets Breakthrough Device Status For DecisionDx-Melanoma Test (RTTNews)
13.01.25		Castle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue Guidance (RTTNews)
06.01.25		Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test (Businesswire)
19.12.24		Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.11.24		Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference (Businesswire)
19.11.24		Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year (Businesswire)
08.11.24		Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting (Businesswire)
07.11.24		Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test (Businesswire)
06.11.24		Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 (Businesswire)
28.10.24		Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
16.10.24		Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential (Businesswire)
14.10.24		Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 (Businesswire)
11.10.24		Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin (Businesswire)
02.10.24		Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas (Businesswire)
18.09.24		SLNO Skyrockets 800%, BWAY Blasts Past 400% - Were You On Board? (RTTNews)
16.09.24		Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year (Businesswire)
11.09.24		DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms (Businesswire)
05.09.24		Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma (Businesswire)
28.08.24		Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
30.07.24		Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference (Businesswire)
22.07.24		Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma (Businesswire)
15.07.24		Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024 (Businesswire)
11.07.24		Castle Biosciences Honored with Top Workplaces Awards (Businesswire)
20.06.24		Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.06.24		Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner (Businesswire)
15.05.24		Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference (Businesswire)
10.05.24		Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution” (Businesswire)
30.04.24		Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma (Businesswire)
11.04.24		Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Businesswire)
10.04.24		Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Businesswire)
10.04.24		Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Businesswire)
04.04.24		Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer (Businesswire)
02.04.24		Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Businesswire)
25.03.24		Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Businesswire)
12.03.24		Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Businesswire)
08.03.24		Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Businesswire)
07.03.24		In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Businesswire)
28.02.24		Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Businesswire)
26.02.24		Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Businesswire)
07.02.24		Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 (Businesswire)
14.01.24		Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii® (Businesswire)
09.01.24		Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report (Businesswire)
20.12.23		Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.12.23		Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results (Businesswire)
14.11.23		Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting (Businesswire)
13.11.23		Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year (Businesswire)
08.11.23		Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie tiefer: Deutsche Bank hebt Kursziel an und bestätigt Kaufempfehlung

Diese Aktien empfehlen Experten zu kaufen

Gold, Öl & Co. in KW 4: Die Tops und Flops unter den Rohstoffen

BVB-Aktie in Grün: 3:0-Erfolg in Berlin: Borussia Dortmund nutzt Schwäche der Bayern für Aufholjagd

Universal Music- und NVIDIA-Aktie im Fokus: Gemeinsame KI-Initiative angekündigt

Österreichische Post-Aktie letztlich stärker: AEP-Anteil verkauft

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2026 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 79% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.01.2026 20:04
Kaufwert:	EUR
	Hinzufügen Speichern

Castle Biosciences Aktie

WKN DE: A2PNH3 / ISIN: US14843C1053

Nachrichten zu Castle Biosciences Inc Registered Shs

Newssuche

Meistgelesene Nachrichten